Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations

Title	Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
Authors	Ainhoa Madariaga, Stephanie Lheureux, Amit M. Oza
Magazine	Cancers
Date	03/23/2019
DOI	10.3390/cancers11030416
Introduction	High grade serous ovarian cancer (HGSOC) is the most prevalent form of epithelial ovarian cancer, characterised by over 20% germline or somatic mutations in BRCA1 and BRCA2 tumour suppressor genes. These genes play critical roles in DNA damage repair through homologous recombination (HR) and transcription regulation. BRCA mutations result in unique responses to DNA-damaging treatments, such as platinum-based chemotherapy and poly-ADP ribose polymerase inhibitors (PARPi). Resistance mechanisms to these treatments have emerged, including enhanced HR through reverse BRCA mutations, changes in non-homologous end-joining (NHEJ) repair, and drug efflux pumps. Current ovarian cancer therapies, encompassing surgery, chemotherapy, targeted treatments, and maintenance strategies, as well as emerging resistance mechanisms, are examined, with a focus on future treatment trends for BRCA mutation carriers.
Quote	Madariaga, A.; Lheureux, S.; Oza, A. M. Customising Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers 2019, 11, 3, 416.
Element	Platinum (Pt)
Topics	Biomedical Materials